China SXT Pharmaceuticals, Inc. (SXTC): Price and Financial Metrics

China SXT Pharmaceuticals, Inc. (SXTC)

Today's Latest Price: $0.70 USD

0.08 (12.59%)

Updated Jan 21 4:00pm

Add SXTC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SXTC Stock Summary

  • With a year-over-year growth in debt of 1,645.91%, China SXT Pharmaceuticals Inc's debt growth rate surpasses 98.69% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, China SXT Pharmaceuticals Inc is reporting a growth rate of -532.36%; that's higher than merely 3.71% of US stocks.
  • As for revenue growth, note that SXTC's revenue has grown -74.91% over the past 12 months; that beats the revenue growth of merely 2.18% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to China SXT Pharmaceuticals Inc are BRFS, VRME, TKC, CENX, and LOMA.
  • Visit SXTC's SEC page to see the company's official filings. To visit the company's web site, go to

SXTC Stock Price Chart Interactive Chart >

Price chart for SXTC

SXTC Price/Volume Stats

Current price $0.70 52-week high $1.48
Prev. close $0.62 52-week low $0.22
Day low $0.62 Volume 20,871,672
Day high $0.77 Avg. volume 16,315,869
50-day MA $0.37 Dividend yield N/A
200-day MA $0.38 Market Cap 24.27M

China SXT Pharmaceuticals, Inc. (SXTC) Company Bio

China Sxt Pharmaceuticals, Inc. engages in the development, manufacture, marketing, sales, research and development of Chinese traditional medicine. It sells Advanced TCMP, Fine TCMP and Regular TCMP products. The company sell its products under "Suxuantang" brand name. The company was founded by Zhou Feng in 2005 and is headquartered in Taizhou, China.

SXTC Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$0.70$0.02 -96%

Below please find a table outlining a discounted cash flow forecast for SXTC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China SXT Pharmaceuticals Inc ranked in the 7th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for SXTC, they are:

  • Its compound free cash flow growth rate, as measured over the past 1.87 years, is -0.24% -- higher than merely 6.79% of stocks in our DCF forecasting set.
  • As a business, SXTC is generating more cash flow than merely 3.98% of positive cash flow stocks in the Healthcare.
  • China SXT Pharmaceuticals Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -2.1. This coverage rate is greater than that of only 17.33% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of China SXT Pharmaceuticals Inc? See NVST, TEVA, INFU, LUMO, and OSMT.

SXTC Latest News Stream

Event/Time News Detail
Loading, please wait...

SXTC Latest Social Stream

Loading social stream, please wait...

View Full SXTC Social Stream

Latest SXTC News From Around the Web

Below are the latest news stories about China SXT Pharmaceuticals Inc that investors may wish to consider to help them evaluate SXTC as an investment opportunity.

Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | November 27, 2020

China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.

Yahoo | March 16, 2020

China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production

NASDAQ-Listed Chinese pharmaceutical company specializing in traditional medicine announces increased production in wake of China government directive

Yahoo | January 24, 2020

Read More 'SXTC' Stories Here

SXTC Price Returns

1-mo 142.80%
3-mo 114.72%
6-mo 58.95%
1-year -21.84%
3-year N/A
5-year N/A
YTD 112.96%
2020 -59.91%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Continue Researching SXTC

Here are a few links from around the web to help you further your research on China SXT Pharmaceuticals Inc's stock as an investment opportunity:

China SXT Pharmaceuticals Inc (SXTC) Stock Price | Nasdaq
China SXT Pharmaceuticals Inc (SXTC) Stock Quote, History and News - Yahoo Finance
China SXT Pharmaceuticals Inc (SXTC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7387 seconds.